Archon Biosciences Analysis: $20M Raised
What is Archon Biosciences?
Archon Biosciences develops geometrically tunable protein therapeutics known as Antibody Cages (AbCs). These biologics leverage generative protein design to target pathways that traditional technologies cannot. The company utilizes structural innovation to create therapeutics with controlled properties for enhanced efficacy.
Location
1616 Eastlake Ave E, Seattle, Washington 98102, United States
Employees
11-50
Founded
2023
Funding Status
Seed
Product Features & Capabilities
- Antibody Cage (AbC) therapeutics
- Generative AI protein design platform
- Structural control for biodistribution and engagement
Use Cases
Targeting previously intractable drug discovery challenges; Designing AbCs for specific biological behaviors; Engineering AbCs for rapid preclinical development; Creating a scalable library of geometric and functional designs; Advancing drug characteristics like manufacturability and immunogenicity
Other Considerations
Co-founded by Nobel Prize winner David Baker; Emerged from stealth mode in 2024; Recognized for pioneering work in computational protein design
See something that needs updating? Suggest edits to this profile.